, Tracking Stock Market Picks
Enter Symbol:
Curis, Inc. (CRIS) [hlAlert]

down 44.69 %

Curis, Inc. (CRIS) rated Outperform with price target $7 by Robert W. Baird

Posted on: Wednesday,  Oct 2, 2013  8:25 AM ET by Robert W. Baird

Robert W. Baird rated Outperform Curis, Inc. (NASDAQ: CRIS) on 10/02/2013, when the stock price was $4.52. Since
then, Curis, Inc. has lost 44.69% as of 01/22/2016's recent price of $2.50.
If you would have followed this Robert W. Baird's recommendation on CRIS, you would have lost 44.69% of your investment in 842 days.

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/2/2013 8:25 AM Buy
4.52 7.00
as of 12/13/2013
1 Week down  -25.94 %
1 Month down  -9.28 %
3 Months down  -43.80 %
1 YTD down  -43.80 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy